RANOLA (Ranolazine) is a newer medication which is indicated in chronic stable angina. Chronic stable angina is a condition in which conventional drugs (beta blockers & calcium channel blockers) are intolerant or give insufficient response and a patient still suffers from angina. It is available as a film-coated, non-scored, extended-release tablet for oral administration.
RANOLA 500mg/1000mg extended release tablets Each extended release tablet contains Ranolazine: 500mg. Each extended release tablet contains Ranolazine: 1000mg.
Chronic stable angina, RANOLA may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.
DOSAGE & ADMINISTRATION:
500 mg twice daily and increase to 1000 mg twice daily, based on clinical symptoms, Take RANOLA with or without meals. Swallow tablets whole; do not crush, break, or chew. The maximum recommended daily dose of RANOLA is 1000 mg twice daily. If a dose of RANOLA is missed, take the prescribed dose at the next scheduled time; do not double the next dose.
Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir). CYP3A inducers (e.g., rifampin, phenobarbital, St. John’s wort) . Liver cirrhosis
Most common adverse reactions are dizziness, headache, constipation, nausea
RANOLA 500mg & 1000mg Extended release tablets; blister pack of 14 tablets
PREGNANCY & LACTATION:
RANOLA should be used during pregnancy only when the potential benefit to the patient justifies the potential risk to the fetus. It should not be used during lactation owing to the fact that it may be excreted in breast milk.